Vaxcyte reports positive topline OPUS-1 data
Vaxcyte said it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.
Vaxcyte said it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.